CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC), the phase III CheckMate 816 trial showed.

Among 358 patients, the 5-year OS rate was 65.4% with nivolumab plus chemotherapy and 55% with chemotherapy alone, (HR 0.72, 95% CI 0.523-0.998, P =0.048), with this improvement consistent across most subgroups, reported Patrick Forde, MBBCh, PhD, of Trinity St. James's Cancer Institute at Trinity College Dublin, at the American Society of Clinical Oncology (ASCO) annual meeting.

"Checkmate 816 is the only phase III trial of neoadjuvant chemoimmunotherapy to demonstrate a statistically significant OS benefit across any resectable solid tumor t

See Full Page